Chimeric Animal Inflammation Treatment Innovation

Publication ID: 24-11856927_0004_PTD
Published: October 26, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Chimeric Animal Inflammation Treatment Innovation,” Published Technical Disclosure No. 24-11856927_0004_PTD, Published October 26, 2025, available at https://archive.pr1or.art/24-11856927_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,856,927.

Background and Problem Solved

The original patent disclosed methods for treating and preventing immune response and inflammation in chimeric animals after birth. However, these methods were not tailored to specific, narrow markets or unique operational environments. The present invention addresses this limitation by providing specialized variations and niche solutions for treating inflammation in chimeric animals after birth, thereby expanding the applicability of the original invention.

Novelty and Inventive Step

The novelty of the present invention lies in the adaptation of the original patent's methods for treating and preventing immune response and inflammation in chimeric animals after birth to specialized environments, such as high-security needs, disaster relief, or extreme weather conditions. The inventive step is the recognition of the need for tailored solutions for these specific markets and the development of compositions and methods that address these needs.

Alternative Embodiments and Variations

Alternative embodiments of the present invention include the use of different anti-inflammatory agents or immunosuppressive agents, or the administration of these agents through different routes or at different stages of the chimeric animal's development. Variations of the invention may also include the use of different types of xenogeneic or allogeneic cells, or the development of new tolerance-inducing agents.

Potential Commercial Applications and Market

The present invention has significant commercial potential in the fields of biotechnology, veterinary medicine, and disaster relief. The invention's ability to provide specialized solutions for treating inflammation in chimeric animals after birth in high-security environments, disaster relief scenarios, or extreme weather conditions addresses a significant unmet need in these markets.

CPC Classifications

SectionClassGroup
A A01 A01K67/0271
A A61 A61K31/573
A A61 A61P37/06
A A01 A01K2217/05
A A01 A01K2217/075
A A01 A01K2227/105
A A01 A01K2267/035
C C12 C12N15/09

Field of Art

Veterinary biotechnology and immunological research, specifically focused on chimeric animal development, stem cell transplantation, and immune system modulation

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in veterinary medicine, immunology, or biotechnology, possessing expertise in stem cell manipulation, immunosuppressive techniques, and chimeric animal research methodologies

Obviousness Rationale

A PHOSITA would recognize that the source patent's core method of managing inflammation in chimeric animals after birth provides a foundational framework that can be readily adapted to specific environmental contexts. The PTD's variations represent predictable extensions of the original patent's core principles, applying known immunosuppressive and anti-inflammatory strategies to specialized scenarios. The technical approach of administering agents to prevent or manage immune responses remains fundamentally consistent across the disclosed variations.

Obvious Combinations & Variations

Source Patent Element
Method of administering anti-inflammatory or immunosuppressive agents to chimeric animals after birth
PTD Variation
Applying the immunosuppressive method in high-security, disaster relief, or extreme weather environments
Obviousness Reasoning
A PHOSITA would recognize that the core immunological management technique is transferable across different operational contexts as a predictable design choice with known therapeutic principles
Source Patent Element
Preventing immune response in xenogeneic or allogeneic chimeric animal fetus individuals
PTD Variation
Introducing tolerance-inducing agents specific to unique operational environments
Obviousness Reasoning
Modifying immunosuppressive approaches for specific contexts represents a routine optimization that would be obvious to a skilled practitioner familiar with adaptive immunological interventions
Source Patent Element
Confirming and treating inflammation after birth in chimeric animals
PTD Variation
Developing compositions combining anti-inflammatory agents with specific cell types for targeted immune management
Obviousness Reasoning
Combining known immunological components with specific cell types is a standard technique in biotechnological research, representing an expected iterative development in the field
Source Patent Element
Method of obtaining adult individuals from chimeric animal fetus individuals with minimal inflammation
PTD Variation
Controlled administration of anti-inflammatory agents in unique operational scenarios
Obviousness Reasoning
Adapting established immunosuppressive protocols to different environmental conditions represents a predictable engineering solution within the scope of ordinary skill
Source Patent Element
Immunodeficient individual treatment approach
PTD Variation
Developing specialized tolerance-inducing systems for high-security environments
Obviousness Reasoning
Extending immunological management techniques to specific contextual requirements is a routine application of known scientific principles
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11856927, the present publication demonstrates that the variations in chimeric animal immune response management represent obvious extensions of prior art, wherein a person having ordinary skill in the art would readily recognize the predictable combinations of known immunological techniques with specific environmental adaptations, thus rendering potential derivative claims obvious and non-patentable.

Original Patent Information

Patent NumberUS 11,856,927
TitleFinding and treatment of inflammation after birth in chimeric animal
Assignee(s)The University of Tokyo